Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus: Moderate Buy — Nine brokerages cover Reviva with a consensus "Moderate Buy" (1 sell, 7 buy, 1 strong buy) and an average 1‑year price target of $3.8571, though several firms have recently trimmed targets (e.g., HC Wainwright $11→$4, Roth $7→$3, Maxim $5→$2).
• Shares are trading very low relative to past highs — opened at $0.62 with a market cap of $70.96M and a 1‑year range of $0.25–$4.28 (50‑ and 200‑day SMAs near $0.54 and $0.56).
• Recent fundamentals and ownership: Reviva beat quarterly EPS estimates (reported -$0.06 vs. -$0.11) while analysts expect -0.97 EPS for the fiscal year, and roughly 63.18% of the stock is held by hedge funds and institutional investors (notable buyers include Armistice, Millennium and Persistent Asset Partners).

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $3.8571.

A number of research analysts have recently commented on the stock. D. Boral Capital restated a "buy" rating and issued a $2.00 price target on shares of Reviva Pharmaceuticals in a report on Wednesday, November 19th. Maxim Group lowered their price objective on shares of Reviva Pharmaceuticals from $5.00 to $2.00 and set a "buy" rating for the company in a research report on Friday, August 15th. Roth Capital reaffirmed a "buy" rating and set a $3.00 target price (down from $7.00) on shares of Reviva Pharmaceuticals in a research report on Monday, August 18th. Chardan Capital upgraded Reviva Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, November 19th. Finally, HC Wainwright dropped their price objective on Reviva Pharmaceuticals from $11.00 to $4.00 and set a "buy" rating on the stock in a research note on Monday, October 27th.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ:RVPH opened at $0.62 on Tuesday. The firm has a market capitalization of $70.96 million, a PE ratio of -1.34 and a beta of -0.02. The business has a 50 day simple moving average of $0.54 and a two-hundred day simple moving average of $0.56. Reviva Pharmaceuticals has a 1 year low of $0.25 and a 1 year high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.05. Equities research analysts expect that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Institutional Trading of Reviva Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in RVPH. Armistice Capital LLC purchased a new position in Reviva Pharmaceuticals during the 2nd quarter valued at about $1,026,000. 683 Capital Management LLC bought a new position in shares of Reviva Pharmaceuticals during the second quarter valued at approximately $381,000. Persistent Asset Partners Ltd increased its holdings in Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company's stock valued at $244,000 after buying an additional 480,864 shares during the period. Millennium Management LLC raised its stake in Reviva Pharmaceuticals by 15.0% in the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company's stock worth $631,000 after buying an additional 223,178 shares in the last quarter. Finally, Lido Advisors LLC purchased a new stake in Reviva Pharmaceuticals during the third quarter worth $37,000. 63.18% of the stock is owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.